NanoEntek Diversifies Supply Channels for 'ADAM-rWBC HT'... "Expanding Market Share in US Blood Products"

[Asia Economy Reporter Jang Hyowon] NanoEntek is accelerating its expansion of market share in the $8 trillion U.S. blood products market through diversification of its sales channels.

On the 4th, NanoEntek announced that it has diversified the supply channels for its ‘ADAM-rWBC HT’ model, which features added high-volume processing technology, primarily targeting large private blood banks in the U.S.

NanoEntek plans to supply an upgraded blood analysis reagent system that has been enhanced from the public to the private sector. Accordingly, an expansion of market share is expected. The ‘ADAM-rWBC HT,’ which includes high-volume processing technology tailored to the needs of large private blood banks in the U.S., can process 50 samples within 50 minutes at once.

The ‘ADAM-rWBC HT’ is approximately 50 times more advanced compared to the existing ‘ADAM-rWBC,’ a technology uniquely possessed only by NanoEntek worldwide. The existing ‘ADAM-rWBC’ was already selected as the standard equipment by the American Red Cross based on its compact size, speed, quality, and price competitiveness. Since it replaces manual work and large equipment, the enhanced performance of the ‘ADAM-rWBC HT’ is expected to accelerate the capture of the U.S. blood products market.

The ‘ADAM-rWBC’ is the first personalized compact automated blood product analysis system developed based on lab-on-a-chip technology. It measures residual white blood cells within one minute to verify the quality of blood products. Currently, it is exclusively supplied to public institutions such as the American Red Cross and military hospitals across the army, navy, and air force in the U.S.

A NanoEntek official explained, “Currently, the existing ‘ADAM-rWBC’ accounts for about 30% of total sales and maintains stable revenue,” adding, “Since high-volume processing has particularly high demand in the private sector within the U.S. market, we expect to expand our sales base into the private sector based on the ‘ADAM-rWBC HT.’”

He continued, “Supply is currently underway mainly to private blood banks, and along with the existing ‘ADAM-rWBC,’ it is expected to serve as a new cash cow.”

Meanwhile, SK Securities researcher Lee Dalmi stated that the North American blood products market is estimated to be approximately $8 trillion in scale.

This content was produced with the assistance of AI translation services.